Oncology Support

RHB-102 (BEKINDA®) (24 mg) is an investigational drug in development for the management of chemotherapy and radiotherapy induced nausea and vomiting, otherwise known as CINV and RINV, in adults.

RHB-102 is a once-daily, bimodal release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, and is intended to provide patients with relief from nausea and vomiting symptoms for a 24-hour period with a single oral tablet.

RHB 102